Betagenon AB

9 articles about Betagenon AB

• Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice

  12/23/2021

  Betagenon AB today announced the publication by co-founder Helena Edlund of a new study demonstrating the prevention and reversal of gene expression and epigenetic changes to beta cells in diet-induced obese mice.

• Betagenon AB announces investment and collaboration with Hong Kong-based MCG Technology Group Ltd

  6/2/2021

  Betagenon AB, a Sweden-based biotech company focused on development of AMPK activator compounds, and MCG Technology Group Ltd, a Hong Kong-based biotech investment group, announced that MCG Technology Group will invest in and collaborate with Betagenon.

• Betagenon AB announces new CEO and new Chairman of the Board

  5/27/2021

  Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, announced that James Hall BM, BCh, D.Phil has joined this month as CEO.

• Dr. Jan M. Lundberg, Former Head of R&D at AstraZeneca and Eli Lilly has Joined Betagenon's Board of Directors

  1/3/2019

  Dr. Jan M Lundberg brings extensive industrial competence to Betagenon

• Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class AMPK Activator O304 in Type 2 Diabetics

  11/2/2017

  Review of the initial data showed that a number of patients who were included based on HbA1c at screening, had FPG below 7 mM or above 13.3 mM at day 1, and that the data analysis of FPG required a post hoc analysis plan.

• Betagenon AB: Start Of Phase IIa Proof-Of-Concept Clinical Trial Of AMPK Activator O304 In Type 2 Diabetics

  8/30/2016

• Betagenon AB: The Small Molecule AMPK Activator O304 Acts As An Oral PCSK9 Inhibitor

  2/2/2015

• Betagenon AB: First Time In Man-AMPK Activator O304

  3/10/2014

• Betagenon AB: AMPK Activator O304, 3-in-1 Drug

  10/24/2011